SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending after its BHV-7000 depression treatment did not meet its primary goal in Phase 2 testing, a development many in the community anticipated. While the news was released during a low-volume holiday period, the company is now refocusing its resources on its promising immunology, obesity, and epilepsy programs. Investors are closely watching for updates from these diverse pipeline assets, particularly the upcoming epilepsy data, as key potential catalysts for future growth.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as the Federal Reserve's recent rate cut and decision to purchase T-bills spark a polarized debate among investors. While some anticipate a rally driven by anticipated lower long-term rates and a weakening economy, others fear persistent inflation and a 'revolting' bond market will push yields higher, making TLT a continued bearish play. The community is closely watching economic data and the Fed's evolving policy stance, with strong opinions on its independence and long-term implications for bond yields.

TOSHI

TOSHI is trending as its community actively "buys the dip," driven by recent exchange listings like Coinone KRW and an "oversold" market status. Discussion centers on its foundational utility on the Base network as the "Face of Base," robust community support, and anticipation of further tier-one listings, positioning it distinctly among meme coins.

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals is trending as analysts reaffirm confidence in its Kv7 drug pipeline, emphasizing that Biohaven's recent depression study miss has limited negative read-through for XENE's distinct azetukalner program. The community is actively discussing the stock's strong analyst ratings and the highly anticipated Phase 3 epilepsy data expected in early 2026, which continues to drive bullish sentiment around its differentiated therapeutic profile.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines, Inc. is trending amid anticipation of an impending FCC ban on Chinese drone components, which is expected to create a significant demand for its U.S.-made, NDAA-compliant parts. The community is buzzing about the company's strategic positioning to capture a large share of the rapidly expanding domestic drone market, further fueled by recent multi-million dollar purchase orders and its reported profitability. This focus on American-made drone technology, supported by major defense spending initiatives, positions UMAC as a key player in the unfolding "Drone Dominance" narrative.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is drawing significant attention following positive clinical data for Tradipitant in addressing GLP-1 induced nausea and vomiting, coupled with multiple near-term regulatory decisions for its pipeline. The community is vigorously debating the stock's undervaluation and considerable growth potential from these catalysts, particularly Tradipitant's role in the expanding GLP-1 market.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth is actively trending amid recent political commentary targeting health insurers and calls for price reductions, fueling community debate on potential impacts and the future of healthcare subsidies. While some anticipate further market volatility and drops, others view the current price action as an opportunity, citing defensive characteristics, ongoing tax-loss harvesting, and the company's strong long-term fundamentals.

British American Tobacco plc is a holding company, which engages in the manufacture and distribution of tobacco products. Its brands include Kent, Dunhill, Lucky Strike, and Pall Mall. It operates through the following geographical segments: United States, Asia-Pacific and Middle East (APME), Americas and Sub-Saharan Africa (AMSSA), and Europe and North Africa (ENA). The APME geographical segment consists of markets in the Middle East merged with Asia-Pacific. The AMSSA geographical segment is composed of markets in East and Central Africa, West Africa, and Southern Africa merged with the Americas region. The ENA geographical segment includes markets in Russia, Ukraine, Caucasus, Central Asia, Belarus, Turkey, and North Africa merged with the Western Europe region. The company was founded by James Buchanan Duke on September 29, 1902 and is headquartered in London, the United Kingdom.

British American Tobacco Plc - ADR

British American Tobacco plc

British American Tobacco is trending due to strong growth in its reduced-risk product portfolio, particularly Velo, and favorable regulatory shifts impacting the broader nicotine sector. Investors are highlighting its robust cash flow, consistent share buybacks, and attractive dividend yield, leading to a largely bullish sentiment and recent analyst upgrades. The company is seen as a resilient investment in the evolving market, attracting attention as a "dividend machine" and a defensive play.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is trending as markets resume, driven by recent robust US GDP growth and unexpectedly lower jobless claims, which are fueling broad market optimism for a "Santa Claus Rally". Community discussion is active on the implications of this economic strength for future Fed policy, while observing the resilience of industrial sectors amidst broader market movements.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics (AAOI) is trending significantly after securing new high-volume orders for its 800G transceivers from hyperscale customers and launching advanced AI-focused lasers, driving considerable analyst upgrades and positive price momentum. The community is actively discussing AAOI's strategic positioning within the rapidly expanding photonics sector crucial for AI data centers, with many believing the company is set for a substantial re-rating as its operational progress aligns with evolving market demands.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Merck reportedly edged out another bidder in late-stage talks that could lead to a deal announcement as soon as Friday.</li><li>Cidara’s CD388 flu antibody, now in phase 3 trials with FDA breakthrough status, has driven significant takeover interest.</li><li>Retail traders debated whether the move signals a full buyout or a milestone-based deal structure.</li></ul><p>Cidara Therapeutics’ shares surged 42% after hours on Thursday following reports that Merck is close to acquiring the biotech in a deal that could be announced as soon as Friday.&nbsp;</p><p>The negotiations reportedly extended late into Thursday as Merck competed with another pharmaceutical group before the seller ultimately favored its offer. The deal is expected to value Cidara above its roughly $3.3 billion market capitalization, though the final price has apparently not been set. Any agreement is likely to include upfront cash and milestone-based payments tied to clinical progress, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/743e1962-3dd1-4785-a20b-4b097e5514ae">report</a> by Financial Times.</p><h2 class="st-heading-2"><strong>Big Pharma Races To Rebuild Pipelines</strong></h2><p>A potential takeover would mark Merck’s latest move to fortify its drug portfolio before Keytruda, its $25 billion-per-year cancer therapy, loses patent protection in 2028. The company agreed in July to buy respiratory drug developer Verona Pharma for $10 billion as part of a broader effort to maintain revenue momentum. The demand for Cidara comes after another big-name auction last week, when&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-loses-metsera-bidding-war-to-pfizer-but-retail-traders-aren-t-losing-faith/cLPcRJWREci">Pfizer narrowly won a race against Novo Nordisk</a> for obesity biotech Metsera in a deal worth as much as $10 billion.</p><h2 class="st-heading-2"><strong>Biotech Sector Heats Up As M&amp;A Wave Accelerates</strong></h2><p>The race for Cidara is unfolding amid a surge in biotechnology dealmaking.&nbsp;<a href="https://stocktwits.com/symbol/XBI">The XBI biotech index</a> has gained over 40% in the past six months as investors bet on a return of acquisitions by big drugmakers looking to add next-generation therapies to their pipelines. The scramble reflects rising urgency across the sector as companies face major revenue losses once key products lose exclusivity.</p><h2 class="st-heading-2"><strong>Cidara’s Lead Flu Antibody Drives Takeover Expectations</strong></h2><p>Cidara’s value surge is tied to its lead program, CD388, a long-acting antibody intended to protect against the two most common strains of influenza. The treatment is being evaluated in phase 3 trials among immunosuppressed patients who cannot receive vaccines, as well as healthy adults over 65. Over 6,000 patients are expected to be enrolled in the studies worldwide by the end of the month. CD388 has been granted an&nbsp;FDA breakthrough designation, which could accelerate regulatory approval. Cidara’s shares have quadrupled since July, driven by strong clinical data and takeover speculation that have fueled investor expectations.</p><h2 class="st-heading-2"><strong>Stocktwits Buzz Highlights Takeover Speculation</strong></h2><p>On Stocktwits, retail sentiment was ‘extremely bullish’ for Cidara and ‘bullish’ for Merck, with both stocks seeing ‘high’ message volume.</p><p>One user reacted to the report by saying, “sounds like $MRK going in for the kill.”</p><p><stembedurl>https://stocktwits.com/JFais/message/636148828</stembedurl></p><p>Another user questioned the structure of the potential deal, writing, “It makes me wonder if it is an actual buyout or an investment in the company for rights to their drug? It mentions the possibility of upfront cash plus milestone payments.... hopefully it is a buyout above the current $150 AH price.”</p><p><stembedurl>https://stocktwits.com/PooPooPewPew/message/636148400</stembedurl></p><p>While&nbsp;<a href="https://stocktwits.com/symbol/CDTX">Cidara’s stock</a> has surged 446% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MRK">Merk’s stock</a> has risen 18% over the same period.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium

Merck reportedly edged out another bidder in late-stage talks that could lead to a deal announcement as soon as Friday.

Equity

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.

All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy

Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.

Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.

Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks 

Shield your portfolio from market swings with low-beta picks like VIPS, GDS, FUTU and VRNA, each showing strong momentum.

Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?

MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.

Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed

MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.

Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?

MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth. 

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

VRNA
Verona Pharma Plc American Depositary

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VRNA News

VRNAVerona Pharma Plc American Depositary